<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. حسب Justine Guguin (9088672)

Wnt signaling decreases the recruitment of RAB8a to basal bodies. حسب Cheng Yuan (160315)

Table of step height. حسب Jianbo Jia (717814)

الموضوعات:

The well wall step. حسب Jianbo Jia (717814)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). حسب Alberto Cornet-Gomez (10676133)

"…The values represent the mean ± SEM, with significance set at p < 0.05 (*).…"

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. حسب Montserrat Llanses Martinez (17797522)

Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes. حسب Annaëlle Le Steunf (19838110)

"…<p>Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes.…"

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. حسب Florentin Pastor (19852287)

الموضوعات: "…chronically infected patients…"

Maximum IFN concentrations are decreased in severe patients. حسب Sonia T. Gazeau (21512764)

Distribution of patients in the 4 age groups, mean value of IC-volume from both sides and separately for the left and right ICs. حسب Pingling Kwok (14896191)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge. حسب Annaëlle Le Steunf (19838110)

"…<p>Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge.…"